(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's ...

The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.